These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33676382)

  • 1. Circulating miR-145 as a marker of therapeutic response to anti-TNF therapy in patients with ankylosing spondylitis.
    Prajzlerová K; Komarc M; Forejtová Š; Pavelka K; Vencovský J; Šenolt L; Filková M
    Physiol Res; 2021 Apr; 70(2):255-264. PubMed ID: 33676382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive values of circulating miR-146a and miR-155 for disease activity and clinical response to TNF-α blocking therapy in patients with ankylosing spondylitis.
    Liu L; Hu X
    Int J Rheum Dis; 2024 Jan; 27(1):e15004. PubMed ID: 38152051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma let-7i, miR-16, and miR-221 levels as candidate biomarkers for the assessment of ankylosing spondylitis in Mexican patients naïve to anti-TNF therapy.
    Reyes-Loyola P; Rodríguez-Henríquez P; Ballinas-Verdugo MA; Amezcua-Castillo LM; Juárez-Vicuña Y; Jiménez-Rojas V; Márquez-Velasco R; Sánchez-Muñoz F; Amezcua-Guerra LM
    Clin Rheumatol; 2019 May; 38(5):1367-1373. PubMed ID: 30911942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients.
    Ciechomska M; Bonek K; Merdas M; Zarecki P; Swierkot J; Gluszko P; Bogunia-Kubik K; Maslinski W
    Arch Immunol Ther Exp (Warsz); 2018 Oct; 66(5):389-397. PubMed ID: 29744553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum miR-214 as a novel biomarker for ankylosing spondylitis.
    Kook HY; Jin SH; Park PR; Lee SJ; Shin HJ; Kim TJ
    Int J Rheum Dis; 2019 Jul; 22(7):1196-1201. PubMed ID: 30729703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.
    Nam B; Koo BS; Lee TH; Shin JH; Kim JJ; Lee S; Joo KB; Kim TH
    BMC Musculoskelet Disord; 2021 Feb; 22(1):140. PubMed ID: 33541326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Serum miR-146a and miR-155 as Novel Noninvasive Complementary Biomarkers for Ankylosing Spondylitis.
    Qian BP; Ji ML; Qiu Y; Wang B; Yu Y; Shi W; Luo YF
    Spine (Phila Pa 1976); 2016 May; 41(9):735-42. PubMed ID: 27128253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients.
    Perez-Sanchez C; Font-Ugalde P; Ruiz-Limon P; Lopez-Pedrera C; Castro-Villegas MC; Abalos-Aguilera MC; Barbarroja N; Arias-de la Rosa I; Lopez-Montilla MD; Escudero-Contreras A; Lopez-Medina C; Collantes-Estevez E; Jimenez-Gomez Y
    Hum Mol Genet; 2018 Mar; 27(5):875-890. PubMed ID: 29329380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy.
    Kwon SR; Lim MJ; Suh CH; Park SG; Hong YS; Yoon BY; Kim HA; Choi HJ; Park W
    Rheumatol Int; 2012 Aug; 32(8):2523-7. PubMed ID: 21833531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy.
    Vastesaeger N; Cruyssen BV; Mulero J; Gratacós Masmitjá J; Zarco P; Almodovar R; Font P; Juanola X; Collantes-Estevez E;
    Reumatol Clin; 2014; 10(4):204-9. PubMed ID: 24598027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
    Saad CG; Ribeiro AC; Moraes JC; Takayama L; Goncalves CR; Rodrigues MB; de Oliveira RM; Silva CA; Bonfa E; Pereira RM
    Arthritis Res Ther; 2012 Oct; 14(5):R216. PubMed ID: 23062122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis.
    Prajzlerová K; Grobelná K; Hušáková M; Forejtová Š; Jüngel A; Gay S; Vencovský J; Pavelka K; Šenolt L; Filková M
    PLoS One; 2017; 12(9):e0185323. PubMed ID: 28938006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of microRNA-132 and its target gene NAG-1 in evaluating therapeutic efficacy of non-steroidal anti-inflammatory drugs treatment in patients with ankylosing spondylitis.
    Guo TM; Yan Y; Cao WN; Liu Q; Zhu HY; Yang L; Gao MC; Xing YL
    Clin Rheumatol; 2018 May; 37(5):1281-1293. PubMed ID: 29497899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy.
    Xueyi L; Lina C; Zhenbiao W; Qing H; Qiang L; Zhu P
    J Clin Immunol; 2013 Jan; 33(1):151-61. PubMed ID: 22926407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
    Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry.
    Tužil J; Mlčoch T; Jirčíková J; Závada J; Nekvindová L; Svoboda M; Uher M; Křístková Z; Vencovský J; Pavelka K; Doležal T
    Expert Opin Biol Ther; 2020 Feb; 20(2):183-192. PubMed ID: 31736377
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunological Changes in Peripheral Blood of Ankylosing Spondylitis Patients during Anti-TNF-
    Chen R; Qian H; Yuan X; Chen S; Liu Y; Wang B; Shi G
    J Immunol Res; 2021; 2021():1017938. PubMed ID: 34692850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-related gene expression in response to TNF inhibitor treatment in ankylosing spondylitis patients: a pilot study.
    Harrison SR; Burska AN; Emery P; Marzo-Ortega H; Ponchel F
    Rheumatology (Oxford); 2021 Aug; 60(8):3607-3616. PubMed ID: 33393636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα.
    Castro-Villegas C; Pérez-Sánchez C; Escudero A; Filipescu I; Verdu M; Ruiz-Limón P; Aguirre MA; Jiménez-Gomez Y; Font P; Rodriguez-Ariza A; Peinado JR; Collantes-Estévez E; González-Conejero R; Martinez C; Barbarroja N; López-Pedrera C
    Arthritis Res Ther; 2015 Mar; 17(1):49. PubMed ID: 25860297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.
    Lord PA; Farragher TM; Lunt M; Watson KD; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2010 Mar; 49(3):563-70. PubMed ID: 20032223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.